M. Scully

发表

The Design of Synthetic Inhibitors of Thrombin

G. Claeson, M. Scully, V. Kakkar, 1993, Advances in Experimental Medicine and Biology.

PLASMINOGEN ACTIVATOR‐DEPENDENT PERICELLULAR PROTEOLYSIS

M. Scully, 1991, British journal of haematology.

Plasminogen activation by single-chain urokinase in functional isolation. A kinetic study.

M. Scully, V. Kakkar, V. Ellis, 1987, The Journal of biological chemistry.

Investigation of the Interaction of Blood Platelets with the Coagulation System at the Site of Plug Formation In Vivo in Man - Effect of Low-Dose Aspirin

J. Westwick, M. Scully, P. Kyrle, 1987, Thrombosis and Haemostasis.

Abstract

M. Scully, V. Kakkar, S. Rahman, 2003 .

Synthesis of ortho-modified mercapto- and piperazino-methyl-phenylboronic acid derivatives

M. Scully, J. Deadman, A. Burd, 2002 .

Thrombolytic therapy.

M. Scully, V. Kakkar, 1968, British medical bulletin.

Evidence for a protein S receptor(s) on human vascular smooth muscle cells. Analysis of the binding characteristics and mitogenic properties of protein S on human vascular smooth muscle cells.

D. Cooper, C. Kanthou, O. Benzakour, 1995, The Biochemical journal.

Inhibition of human factor Xa by various plasma protease inhibitors.

M. Scully, V. Kakkar, V. Ellis, 1982, Biochimica et biophysica acta.

The relative molecular mass dependence of the anti-factor Xa properties of heparin.

M. Scully, V. Kakkar, V. Ellis, 1986, The Biochemical journal.

A rapid method for the isolation of coagulation factor XII from human plasma

M. Scully, V. Kakkar, K. Weerasinghe, 1985 .

Identification of heparin cofactor II as the principal plasma cofactor for the antithrombin activity of pentosan polysulphate (SP54).

M. Scully, V. Kakkar, 1984, Thrombosis research.

Structural features of fibrinogen associated with binding to chelated zinc.

M. Scully, V. Kakkar, 1982, Biochimica et biophysica acta.

Role of thrombin in pulmonary fibrosis

R. Chambers, M. Scully, R. McAnulty, 1995, The Lancet.

Tissue factor pathway inhibitor in endothelial cells colocalizes with glycolipid microdomains/caveolae. Regulatory mechanism(s) of the anticoagulant properties of the endothelium.

M. Scully, V. Kakkar, J. Emeis, 1997, Arteriosclerosis, thrombosis, and vascular biology.

Acquired Dysfibrinogenaemia in Acute and Chronic Liver Disease

M. Scully, D. Lane, D. Thomas, 1977, British journal of haematology.

Prothrombin cleavage by human vascular smooth muscle cells: A potential alternative pathway to the coagulation cascade

D. Cooper, C. Kanthou, O. Benzakour, 1995, Journal of cellular biochemistry.

Identification of a cyclic peptide inhibitor of platelet‐derived growth factor–BB receptor‐binding and mitogen‐induced DNA synthesis in human fibroblasts

M. Scully, V. Kakkar, V. Ellis, 1997, FEBS letters.

Non-specific influence of chemical modification upon the properties of antithrombin III:modification of carboxyl groups.

M. Scully, V. Kakkar, C. Goodwin, 1992, Thrombosis research.

Comparison of the molecular mass dependency of heparin stimulation of heparin cofactor II:thrombin interaction to antithrombin III:thrombin interaction.

M. Scully, V. Kakkar, V. Ellis, 1987, Thrombosis research.

Anticoagulant and antiheparin activities of a pentosan polysulphate.

M. Scully, V. Kakkar, V. Ellis, 1983, Thrombosis research.

Inhibition Of Human Factor Xa By Various Plasma Protease Inhibitors

M. Scully, V. Kakkar, V. Ellis, 1982, Thrombosis and Haemostasis.

Methods for semi micro or automated determination of thrombin, antithrombin, and heparin cofactor using he substrate, H-D-Phe-Pip-Arg-p-nitroanilide-2HCl.

M. Scully, V. Kakkar, 1977, Clinica chimica acta; international journal of clinical chemistry.

Comparison of the effects of low molecular weight heparin and unfractionated heparin on activation of human platelets in vitro.

J. Westwick, M. Scully, V. Kakkar, 1986, Thrombosis research.

Influence of Intrinsic and Extrinsic Plasminogen upon the Lysis of Thrombi In Vitro

M. Scully, V. Kakkar, N. Nishino, 1991, Thrombosis and Haemostasis.

Arg-Tyr-Asp (RYD) and Arg-Cys-Asp (RCD) motifs in dendroaspin promote selective inhibition of beta1 and beta3 integrins.

M. Scully, V. Kakkar, S. Rahman, 2001, The Biochemical journal.

Evaluation of the role of proline residues flanking the RGD motif of dendroaspin, an inhibitior of platelet aggregation and cell adhesion.

M. Scully, V. Kakkar, X. Lu, 2001, The Biochemical journal.

Inhibition of airway smooth muscle adhesion and migration by the disintegrin domain of ADAM-15.

K. Chung, M. Scully, Xinjie Lu, 2007, American journal of respiratory cell and molecular biology.

Mechanisms of Stimulus—Response Coupling in Platelets

J. Westwick, M. Scully, D. Macintyre, 1985, Advances in Experimental Medicine and Biology.

Hereditary Antithrombin III Deficiency in an English Family

M. Scully, V. Kakkar, H. D. Haas, 1981, British journal of haematology.

High-affinity binding sites for heparin generated on leukocytes during apoptosis arise from nuclear structures segregated during cell death.

M. Scully, V. Kakkar, A. Gruszka-Westwood, 2002, Blood.

Arg-Tyr-Asp (RYD) and Arg-Cys-Asp (RCD) motifs in dendroaspin promote selective inhibition of β1 and β3 integrins

M. Scully, V. Kakkar, S. Rahman, 2022 .

Thrombin induces the redistribution and acute release of tissue factor pathway inhibitor from specific granules within human endothelial cells in culture.

M. Scully, V. Kakkar, C. Lupu, 1995, Arteriosclerosis, thrombosis, and vascular biology.

MEASUREMENT OF HEPARIN IN PLASMA: INFLUENCE OF INTER-SUBJECT AND CIRCADIAN VARIABILITY IN HEPARIN SENSITIVITY ACCORDING TO METHOD

M. Scully, V. Kakkar, V. Ellis, 1987, Thrombosis and Haemostasis.

Pentosan polysulphate: activation of heparin cofactor II or antithrombin III according to molecular weight fractionation.

M. Scully, V. Kakkar, V. Ellis, 1986, Thrombosis research.

Low-molecular-weight heparin and prevention of postoperative deep vein thrombosis.

J. Westwick, M. Scully, V. Kakkar, 1982, British medical journal.

Structure-activity relationship studies on ADAM protein-integrin interactions.

M. Scully, V. Kakkar, X. Lu, 2007, Cardiovascular & hematological agents in medicinal chemistry.

The Potential Thrombogenic Action of a Nonionic Radiographic Contrast Medium Used during Coronary Angiography Is Offset by Heparin during Coronary Angioplasty

M. Scully, V. Kakkar, D. Jewitt, 1996, Thrombosis and Haemostasis.

ENHANCED IN-VIVO PLATELET RELEASE REACTION, INCREASED THROMBOXANE SYNTHESIS, AND DECREASED PROSTACYCLIN RELEASE AFTER TOURNIQUET ISCHAEMIA

J. Westwick, M. Scully, V. Kakkar, 1980, The Lancet.

LOCALISATION OF HEPARIN IN MAST CELLS

M. Scully, V. Kakkar, V. Ellis, 1986, The Lancet.

Late-onset homozygous protein C deficiency

M. Scully, E. Melissari, V. Kakkar, 1991, The Lancet.

Inhibition of prothrombinase complex by plasma proteinase inhibitors.

M. Scully, V. Kakkar, V. Ellis, 1984, Biochemistry.

An Experimental Model for the Study of Venous Thrombosis in Vivo

M. Scully, P. Gaffney, T. K. Day, 1974, Thrombosis and Haemostasis.

Severe antigenic deficiency of protein C associated with moderate deficiency of protein C activity.

M. Scully, V. Kakkar, V. Ellis, 1985, Thrombosis research.

Mechanisms of inhibition of platelet coagulant activity.

M. Scully, V. Kakkar, V. Ellis, 1985, Advances in experimental medicine and biology.

The influence of LMW heparin on the coagulation and fibrinolytic response to surgery.

M. Scully, V. Kakkar, E. Melissari, 1985, Thrombosis research.

Do prostacyclin and thromboxane play a role in endotoxic shock?

J. Westwick, M. Scully, J. Zahavi, 1981, The British journal of surgery.

A cyclic peptide analogue of loop III of PDGF‐BB causes apoptosis in human fibroblasts

M. Scully, V. Kakkar, D. Brennand, 1997, FEBS letters.

Increased expression of procoagulant activity on the surface of human platelets exposed to heavy-metal compounds.

M. Scully, V. Kakkar, C. Wheeler-Jones, 1995, The Biochemical journal.

Annexin V as a probe of the contribution of anionic phospholipids to the procoagulant activity of tumour cell surfaces.

M. Scully, R. Donato, M. Sugimura, 1994, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Fibrin subunits in venous and arterial thromboembolism.

M. Scully, P. Gaffney, V. Kakkar, 1976, Cardiovascular research.

The problem of infection after prostatic biopsy: the case for the transperineal approach.

M. Scully, V. Kakkar, J. Williams, 1982, British journal of urology.

Fibrinogen subunit degradation in vitro: studies on human fibrinogen heterogeneity.

M. Scully, V. Kakkar, D. Lane, 1976, Thrombosis research.

Introduction

M. Scully, 1991 .

Mercury compounds induce a rapid increase in procoagulant activity of monocyte‐like U937 cells

M. Scully, V. Kakkar, H. Kaneko, 1994, British journal of haematology.

Snake venom metalloproteinase containing a disintegrin-like domain, its structure-activity relationships at interacting with integrins.

M. Scully, V. Kakkar, X. Lu, 2005, Current medicinal chemistry. Cardiovascular and hematological agents.

Binding of fibrinogen fragment D to chelated zinc: localization of a possible binding site.

M. Scully, V. Kakkar, 1983, Thrombosis Research.

The Effect of Collagen Mediated Platelet Release on Plasma Prekallikrein Activation

M. Scully, V. Kakkar, K. Weerasinghe, 1984, Thrombosis and Haemostasis.

Activation of pro-urokinase by plasmin: non-Michaelian kinetics indicates a mechanism of negative cooperativity.

M. Scully, V. Kakkar, V. Ellis, 1989, Archives of biochemistry and biophysics.

Plasminogen activation initiated by single-chain urokinase-type plasminogen activator. Potentiation by U937 monocytes.

M. Scully, V. Kakkar, V. Ellis, 1989, The Journal of biological chemistry.

The behavior of isotope labelled blood proteins in thrombosis.

M. Scully, V. Kakkar, C. Strachan, 1974, Thrombosis research.

Method for the determination of plasminogen which discriminates between native and degraded plasminogen.

M. Scully, V. Kakkar, 1978, Thrombosis research.

G. Claeson, M. Scully, V. Kakkar, 1991 .

Evaluation of a chromogenic method for endotoxin measurement.

M. Scully, V. Kakkar, S. Clark, 1980, Thrombosis research.

Plasma levels of tissue factor pathway inhibitor in thrombophilic patients.

M. Scully, E. Melissari, V. Kakkar, 1993, Thrombosis research.

An acquired coagulation inhibitor to factor II

M. Scully, V. Ellis, G. Savidge, 1982, British journal of haematology.

In vitro and in vivo characterization of a neutral boron-containing thrombin inhibitor.

G. Claeson, M. Scully, M. Zurini, 1993, The Journal of biological chemistry.

The use of isosteric bonds in the design of thrombin inhibitors.

G. Claeson, M. Scully, V. Kakkar, 1993, Advances in experimental medicine and biology.

E. Skordalakes, M. Scully, V. Kakkar, 1996 .

Structure/function aspects of neutral P1 residue peptide inhibitors of thrombin.

G. Claeson, M. Scully, J. Deadman, 1995, Journal of enzyme inhibition.

Inhibition of human alpha-thrombin by a phosphonate tripeptide proceeds via a metastable pentacoordinated phosphorus intermediate.

E. Skordalakes, M. Scully, V. Kakkar, 2001, Journal of molecular biology.

Facile routes to 1-halo-1-alkyl boronic esters as precursors for novel thrombin inhibitors

G. Claeson, M. Scully, V. Kakkar, 1994 .

X-Ray Crystallographic Analyses of Human α-Thrombin Complexed to Peptidyl Aminophosphonates: Evidence of a Binding Mechanism

E. Skordalakes, M. Scully, V. Kakkar, 1999 .

Influence of heparin and various glycosaminoglycans on activation of single chain urokinase-type plasminogen activator (scu-PA) by plasmin

M. Scully, V. Kakkar, V. Ellis, 1989 .

Modulation of the Cell Binding Property of Single Chain Urokinase-type Plasminogen Activator by Neutrophil Cathepsin G

M. Scully, V. Kakkar, W. Li, 1992 .

Fibronectin in fulminant hepatic failure.

M. Scully, R. Hughes, R. Williams, 1982, British medical journal.

The anticoagulant properties of mast cell product, chondroitin sulphate E.

M. Scully, V. Kakkar, V. Ellis, 1986, Biochemical and biophysical research communications.

Influence of Whole Blood on Standard Curve for Heparin Measurement - Possible Heparin Binding by Red Cells

M. Scully, V. Kakkar, E. Melissari, 1989, Thrombosis and Haemostasis.

ADAM proteins - therapeutic potential in cancer.

M. Scully, V. Kakkar, Xinjie Lu, 2008, Current cancer drug targets.

The Role of Integrins in Cancer and the Development of Anti-Integrin Therapeutic Agents for Cancer Therapy

M. Scully, V. Kakkar, Xinjie Lu, 2008, Perspectives in medicinal chemistry.

Cold adaptation and the seasonal distribution of acute myocardial infarction.

M. Scully, V. Kakkar, F. de Lorenzo, 1999, QJM : monthly journal of the Association of Physicians.

The Effect of the Single Substitution of Arginine within the RGD Tripeptide Motif of a Modified Neurotoxin Dendroaspin on Its Activity of Platelet Aggregation and Cell Adhesion

M. Scully, V. Kakkar, M. Xia, 2006, Cell communication & adhesion.

A comparative study of low doses of heparin and a heparin analogue in the prevention of postoperative deep vein thrombosis.

P. G. Bentley, M. Scully, V. Kakkar, 1978, Thrombosis Research.

A Case of Familial Antithrombin III Deficiency in an English Family

M. Scully, V. Kakkar, S. Clark, 1979, Thrombosis and Haemostasis.

A platelet derived inhibitor of plasma prekallikrein activation.

M. Scully, V. Kakkar, K. Weerasinghe, 1983, Thrombosis Research.

Prolonged thrombin clotting times in liver disease.

M. Scully, V. Kakkar, D. Lane, 1977, Thrombosis research.

ANTITHROMBIN III AND HEPARIN

P. G. Bentley, M. Scully, V. Kakkar, 1980, The Lancet.

Automated Control of Coumarin Therapy by Chromogenic Factor X Assay

M. Scully, I. Macgregor, R. Mibashan, 1979, Thrombosis and Haemostasis.

The Influence of DDAVP Infusion on the Coagulation and Fibrinolytic Response to Surgery

M. Scully, V. Kakkar, V. Ellis, 1986, Thrombosis and Haemostasis.

Influence of chemical modification of tryptophan residues on the properties of human antithrombin III.

M. Scully, V. Kakkar, V. Ellis, 1990, Thrombosis research.

Heparan sulphate with no affinity for antithrombin III and the control of haemostasis

M. Scully, V. Kakkar, V. Ellis, 1988, FEBS letters.

An objective study of alternative methods of heparin administration.

P. G. Bentley, M. Scully, V. Kakkar, 1980, Thrombosis research.

Studies of anti-Xa activity.

M. Scully, V. Kakkar, V. Ellis, 1983, Thrombosis research.

Platelet interaction with the contact system of coagulation.

M. Scully, V. Kakkar, K. M. Weersinghe, 1985, Advances in experimental medicine and biology.

Inhibition of the cerebroside sulphate (sulphatide)-induced contact activation reactions by platelet factor four.

M. Scully, V. Kakkar, K. Weerasinghe, 1984, Thrombosis research.

Inhibition Of Contact Activation By Platelet Factor 4

M. Scully, V. Kakkar, K. Weerasinghe, 1980, Thrombosis and Haemostasis.

Protein S and C4b‐binding protein in fetal and neonatal blood

K. Nicolaides, M. Scully, V. Kakkar, 1988, British journal of haematology.

15 Deoxy Δ12,14 PGJ2 Induces Procoagulant Activity in Cultured Human Endothelial Cells

M. Scully, V. Kakkar, D. O'regan, 2002, Thrombosis and Haemostasis.

ADAM-15 Disintegrin-Like Domain Structure and Function

M. Scully, V. Kakkar, Xinjie Lu, 2010, Toxins.

A method for characterising serum fibrinogen and fibrin degradation products.

M. Scully, V. Kakkar, D. Lane, 1976, Thrombosis research.

Activation of Protein C and Its Distribution between Its Inhibitors, Protein C Inhibitor, α1-Antitrypsin and α2-Macroglobulin, in Patients with Disseminated intravascular Coagulation

M. Scully, M. Nesheim, H. Hoogendoorn, 1993, Thrombosis and Haemostasis.

Potentiation by Lys-Plasminogen of Clot Lysis by Single or Two Chain Urokinase-Type Plasminogen Activator or Tissue-Type Plasminogen Activator

M. Scully, V. Kakkar, V. Ellis, 1989, Thrombosis and Haemostasis.

Binding of Iodinated Proteins to Forming and Preformed Thrombi

M. Scully, V. Kakkar, C. Strachan, 1973 .

Plasma peptidome: A new approach for assessing thrombotic risk?

M. Scully, 2006, Thrombosis and Haemostasis.

Inability of dithiols to cause activation ofLimulus endotoxin sensitive procoagulase

M. Scully, V. Kakkar, Y. M. Newman, 1981, Experientia.

Inhibition of fibrinolytic activity by hyaluronan and its alcohol ester derivatives.

M. Scully, M. O'regan, V. Kakkar, 1995, Thrombosis research.

Measurement of degraded forms of plasminogen in human plasma.

M. Scully, V. Kakkar, 1980, Thrombosis research.

The acceleration of the inhibition of platelet prothrombinase complex by heparin.

M. Scully, V. Kakkar, V. Ellis, 1986, The Biochemical journal.

G. Claeson, M. Scully, J. Deadman, 1993, Advances in Experimental Medicine and Biology.

Early interaction of radioactive butylated hydroxytoluene with protein factors of varying stability in rat liver, related to the onset of sequential biochemical changes leading to the induction of drug-metabolizing enzymes and liver enlargment.

M. Scully, P. J. Bray, J. Nievel, 1976, Biochemical Society transactions.

Platelet activation during steady state sickle cell disease.

J. Westwick, M. Scully, V. Kakkar, 1983, Journal of medicine.

Integrin binding characteristics of the disintegrin-like domain of ADAM-15

K. Chung, M. Scully, V. Kakkar, 2006, Thrombosis and Haemostasis.

Generation of ligand conformations in continuum solvent consistent with protein active site topology: application to thrombin.

Jörg Weiser, Paulette A Greenidge, M. Scully, 2003, Journal of medicinal chemistry.

A Chromogenic Semi-Micro Method for the Determination of Factor Xa, Factor Xa Inhibitor and Mini-Dose Heparin Levels

M. Scully, V. Kakkar, 1977, Thrombosis and Haemostasis.

Integrins in drug targeting-RGD templates in toxins.

M. Scully, V. Kakkar, V V Kakkar, 2006, Current pharmaceutical design.

Zn2+-chelate chromatography of human fibrinogen

M. Scully, V. Kakkar, 1981 .

Zinc Chelate Chromatography Of Fibrinogen

M. Scully, V. Kakkar, 1981, Thrombosis and Haemostasis.

Design of a novel class of bifunctional thrombin inhibitors, synthesised by the first application of peptide boronates in solid phase chemistry

E. Skordalakes, M. Scully, V. Kakkar, 1997 .

Thrombin receptor activating peptide does not stimulate platelet procoagulant activity.

M. Scully, J. Deadman, C. Wheeler-Jones, 1994, Biochemical and Biophysical Research Communications - BBRC.

Modulation of integrin-binding selectivity by mutation within the RGD-loop of snake venom proteins: a novel drug development approach.

M. Scully, V. Kakkar, D. Lu, 2003, Current Medicinal Chemistry - Cardiovascular & Hematological Agents.

The role of integrin-mediated cell adhesion in atherosclerosis: pathophysiology and clinical opportunities.

M. Scully, V. Kakkar, D. Lu, 2008, Current pharmaceutical design.

15 deoxy delta12,14 PGJ2 induces procoagulant activity in cultured human endothelial cells.

M. Scully, V. Kakkar, S. Xie, 2002, Thrombosis and haemostasis.